Economics of Innovation
Optimal innovation balances willingness and ability to pay with the benefits of future R&D. Our wide-ranging programme aims to promote innovation in health care, increase our understanding of its value, and encourage R&D. New models of innovation should streamline development, reduce costs, and speed patient benefit.
New Drugs to Tackle Antimicrobial Resistance: EU Policy Options
1 October 2010
Antimicrobial resistance (AMR) to drugs, a natural and unavoidable consequence of treating infectious diseases, is a growing global public health threat. The EU Commission is to…
Innovation in Medicines: Can We Value Progress?
1 August 2010
Summarised in this publication are the main points and conclusions from a discussion facilitated by OHE that focused on innovation in the pharmaceutical industry. Participants included…
Forward Together: Complementarity of Public and Charitable Research with Respect to Private Research Spending
9 January 2009
The debate continues as to whether public/charitable research replaces private research that otherwise would have occurred, or stimulates additional private research, or does neither. Given the…
Deliberative Processes in Decisions about Health Care Technologies
1 June 2009
In the UK and elsewhere, choices about how to allocate health care resources are guided not only by economic calculations, but also by social value judgments…
The Impact of Health Technology Assessment on Drug Development
3 January 2009
Health technology assessment (HTA) has become a critical basis for pricing and reimbursement decision-making worldwide. In some countries, extensive requirements for data are set out in…
The Market for Biosimilars: Evolution and Policy Options
1 November 2008
The authors point out that biopharmaceuticals are more complex agents than conventional chemical entities and therefore are more difficult to replicate after patent expiry. Off-patent versions…
Donor Investment Choices: Modeling the Value for Money of Investing in Product Development, Public Private Parnerships as Compared to Other Health Care and Non-Health Care Interventions
1 December 2006
Objective To model the cost-effectiveness for donors of investing in R&D projects into global diseases via public private partnerships for product development (PD PPPs). Methods We…
Saving Lives, Buying Time: Economics of Malaria Drugs in an Age of Resistance
1 November 2006
This Annual Lecture took place on the 10 November 2005 at the Royal College of Physicians and was presented by Kenneth Arrow and Richard Peto.… This…
The Faces of Regulation: Profit and Price Regulation of the UK Pharmaceutical Industry after the 1998 Competition Act
1 May 2006
This Briefing discusses, inter alia, the role of the Office of Fair Trading (OFT) in competition cases affecting the pharmaceutical industry. It does so in the…